Mcintyre Freedman & Flynn Investment Advisers Inc. Sells 244 Shares of Johnson & Johnson (NYSE:JNJ)

Mcintyre Freedman & Flynn Investment Advisers Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,948 shares of the company’s stock after selling 244 shares during the period. Mcintyre Freedman & Flynn Investment Advisers Inc.’s holdings in Johnson & Johnson were worth $1,728,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Cornerstone Advisors LLC grew its holdings in Johnson & Johnson by 2.7% during the 4th quarter. Cornerstone Advisors LLC now owns 123,402 shares of the company’s stock valued at $17,846,000 after buying an additional 3,300 shares in the last quarter. Sage Mountain Advisors LLC lifted its position in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after buying an additional 67 shares during the last quarter. Riverbend Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $669,000. Claris Advisors LLC MO lifted its position in Johnson & Johnson by 38.1% in the fourth quarter. Claris Advisors LLC MO now owns 2,065 shares of the company’s stock valued at $299,000 after purchasing an additional 570 shares during the last quarter. Finally, Vista Investment Partners II LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $523,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.5 %

NYSE:JNJ opened at $167.57 on Tuesday. The firm has a market cap of $403.45 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $153.44 and a 200 day moving average price of $156.28. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 2.96%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. Bank of America increased their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.